Suppr超能文献

单一移植中心肝细胞癌肝移植的临床与病理分期及长期结果比较

Comparison of clinical and pathological staging and long-term results of liver transplantation for hepatocellular carcinoma in a single transplant center.

作者信息

Baccarani U, Adani G L, Avellini C, Lorenzin D, Currò G, Beltrami A, Pasqualucci A, Bresadola V, Risaliti A, Viale P L, Beltrami C A, Bresadola F

机构信息

Department of Surgery and Transplantation, University Hospital Udine, Italy.

出版信息

Transplant Proc. 2006 May;38(4):1111-3. doi: 10.1016/j.transproceed.2006.02.015.

Abstract

Liver transplantation (OLT) is a treatment for hepatocellular carcinoma (HCC) superimposed on cirrhosis provided that the disease meets defined criteria. The aim of the study was to evaluate our experience with respect to clinical and pathological staging and long-term results. From 1996 to 2005, 50 patients underwent OLT for HCC including 43 men (86%) and seven women (14%) of median age 57 years (range 37 to 67). All patients fulfilled the Milan criteria. The HCC diagnosis was based on preoperative imaging and alpha-fetoprotein levels; no tumor biopsy was performed. Upon histological examination of the resected specimens, we discovered 6 (12%) incidentalomas and 8 (16%) cases of no HCC. Finally we had 42 "true" HCC. Twenty-six patients (52%) have been downstaged and 10 (20%) upstaged by preoperative imaging; 15% were pT1, 45% were pT2, 27% pT3, and 13% pT4a. Twenty-six percent of cases exceeded the Milan criteria. One patient (pT4a) with microvascular invasion died of pulmonary metastases at 14 months after transplantation. No HCC recurrences within the liver have been encountered at a median follow-up of 20 months (range 0 to 80 months). Overall the estimated 1-, 3-, and 5-year survival rates were 83%, 77%, and 72%, respectively. One-, 3-, and 5-year estimated survival rates were 87%, 75%, and 75% for pT1, and pT2, and 75%, 67%, and 67% for pT3 and pT4a, respectively (P = .99). Based on our experience OLT for HCC has long-term results comparable to those without HCC despite the presence of a significant number of cases exceeding the Milan criteria upon pathological staging.

摘要

肝移植(OLT)是治疗合并肝硬化的肝细胞癌(HCC)的一种方法,前提是该疾病符合既定标准。本研究的目的是评估我们在临床和病理分期以及长期结果方面的经验。1996年至2005年,50例患者接受了针对HCC的OLT,其中包括43名男性(86%)和7名女性(14%),中位年龄57岁(范围37至67岁)。所有患者均符合米兰标准。HCC诊断基于术前影像学检查和甲胎蛋白水平;未进行肿瘤活检。在对切除标本进行组织学检查时,我们发现了6例(12%)偶然瘤和8例(16%)无HCC病例。最终我们有42例“真正的”HCC。26例患者(52%)术前影像学检查显示分期降低,10例(20%)分期升高;15%为pT1,45%为pT2,27%为pT3,13%为pT4a。26%的病例超出了米兰标准。1例伴有微血管侵犯的患者(pT4a)在移植后14个月死于肺转移。在中位随访20个月(范围0至80个月)时,未发现肝内HCC复发。总体而言,估计的1年、3年和5年生存率分别为83%、77%和72%。pT1和pT2的1年、3年和5年估计生存率分别为87%、75%和75%,pT3和pT4a的分别为75%、67%和67%(P = .99)。基于我们的经验,尽管在病理分期时有相当数量的病例超出米兰标准,但针对HCC的OLT的长期结果与无HCC的情况相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验